Drug Trial Radar · NCT04513925
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
829
Actual
Start
Aug 24, 2020
Primary completion
May 27, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Aug 14, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
Interventions
AtezolizumabDrug
Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.
TiragolumabDrug
Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.
DurvalumabDrug
Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight \>/= 30 kg) on Day 1 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS), as Assessed by an Independent Review Facility (IRF) in Programmed Death-ligand 1 (PD-L1) Positive Analysis Set (PPAS)Time frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
- PFS, as Assessed by an IRF in FASTime frame: From randomization to first occurrence of PD or death from any cause, whichever occurred first (up to approximately 57 months)
Locations
189 sites in 26 countries. Site status is shown where the registry gives one.
Stanford University
Palo Alto, California
Banner MD Anderson Cancer Center
Greeley, Colorado
Florida Cancer Specialists
Fort Myers, Florida
Cancer Care Centers of Brevard
Palm Bay, Florida
Woodlands Medical Specialists, P.A.
Pensacola, Florida
Florida Cancer Specialist, North Region
St. Petersburg, Florida
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia
Illinois Cancer Care
Peoria, Illinois
New England Cancer Specialists
Brunswick, Maine
Southcoast Health System
Fairhaven, Massachusetts
Minnesota Oncology Hematology
Minneapolis, Minnesota
HCA Midwest Health
Kansas City, Missouri
Cox Health Systems
Springfield, Missouri
Optum Health Care
Las Vegas, Nevada
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Titan Health Partners LLC, d/b/a Astera Cancer Care
East Brunswick, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
New York Oncology Hematology,P.C.-Albany
Albany, New York
Mount Sinai Medical Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Prisma Health ? Upstate
Greenville, South Carolina
Tennessee Oncology Chattanooga
Chattanooga, Tennessee
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee
Virginia Cancer Specialists
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
CEMIC
Buenos Aires, Argentina
Hospital Britanico de Buenos Aires
Ciudad Autonoma Buenos Aires, Argentina
Clinica Universitaria Reina Fabiola
Córdoba, Argentina
Sanatorio Parque S.A.
Rosario, Argentina
Blacktown Hospital
Blacktown, New South Wales, Australia
Macarthur Cancer Therapy Centre
Campbelltown, New South Wales, Australia
St George Hospital
Kogarah, New South Wales, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Monash Health Translational Precinct
Victoria, Victoria, Australia
Fiona Stanley Hospital
Bull Creek, Western Australia, Australia
Tiroler Landeskrankenanstalten Ges.M.B.H.
Innsbruck, Austria
Kepler Universitätskliniken GmbH - Med Campus III
Linz, Austria
Klinik Penzing
Vienna, Austria
GHdC Site Les Viviers
Charleroi, Belgium
AZ Maria Middelares
Ghent, Belgium
Showing 40 of 189 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.